Synairgen gained the spotlight at the European Respiratory Society meeting in Vienna, posting positive mid-stage data on a drug that combats asthma attacks triggered by infections. Investigators say that the 134-patient study demonstrated that SNG001 prevented symptoms of asthma during the first week of an infection. And the biotech, based in Southampton, U.K., says the data will help accelerate partnership talks. The study delivered a solid 65% reduction in the number of attacks when compared to the placebo arm. "This is the patient group most in need of new approaches and is an area of great interest for the large biotech and pharma companies that we are talking to," CEO Richard Marsden told Bloomberg. The results pushed in Synairgen's shares by about 6%. Story